Real-World Efficacy and Safety of Fluocinolone Acetonide Implant for Diabetic Macular Edema: A Systematic Review
| dc.rights.license | open | en_US |
| dc.contributor.author | KODJIKIAN, L. | |
| dc.contributor.author | BAILLIF, S. | |
| dc.contributor.author | CREUZOT-GARCHER, C. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | DELYFER, Marie-Noelle | |
| dc.contributor.author | MATONTI, F. | |
| dc.contributor.author | WEBER, M. | |
| dc.contributor.author | MATHIS, T. | |
| dc.date.accessioned | 2021-03-01T13:25:11Z | |
| dc.date.available | 2021-03-01T13:25:11Z | |
| dc.date.issued | 2021-01-07 | |
| dc.identifier.issn | 1999-4923 (Print) 1999-4923 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/26387 | |
| dc.description.abstractEn | To assess real-world outcomes of fluocinolone acetonide (FAc) implant in treating diabetic macular edema (DME), a systematic literature review was conducted on PubMed in order to identify publications assessing the efficacy and safety of the FAc implant in DME in daily practice. Case reports and randomized controlled trials were excluded. Twenty-two observational real-world studies analyzing a total of 1880 eyes were included. Mean peak visual gain was +8.7 letters (11.3 months post-FAc injection) and was greater for lower baseline best corrected visual acuity (BCVA) and for more recent DME. Mean central retinal thickness (CRT) decreased 34.3% from baseline. 77.0% of the analyzed studies reported both BCVA improvement of at least five letters and a CRT decrease by 20% or more. Rescue therapy was needed more frequently when FAc was administered for chronic DME. FAc-induced ocular hypertension was reported in 20.1% of patients but only 0.6% needed surgery. Cataract extraction was performed in 43.2% of phakic patients. Adequate patient selection is essential for optimal FAc response and better safety profile. Currently positioned as second- or third-line treatment in the management algorithm, FAc implant decreases treatment burden and provides better letter gain when administered for more recent DME. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.title.en | Real-World Efficacy and Safety of Fluocinolone Acetonide Implant for Diabetic Macular Edema: A Systematic Review | |
| dc.title.alternative | Pharmaceutics | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.3390/pharmaceutics13010072 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 33430389 | en_US |
| bordeaux.journal | Pharmaceutics | en_US |
| bordeaux.volume | 13 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - U1219 | en_US |
| bordeaux.issue | 1 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | LEHA_BPH | |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03154997 | |
| hal.version | 1 | |
| hal.date.transferred | 2021-03-01T13:25:15Z | |
| hal.export | true | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Pharmaceutics&rft.date=2021-01-07&rft.volume=13&rft.issue=1&rft.eissn=1999-4923%20(Print)%201999-4923%20(Linking)&rft.issn=1999-4923%20(Print)%201999-4923%20(Linking)&rft.au=KODJIKIAN,%20L.&BAILLIF,%20S.&CREUZOT-GARCHER,%20C.&DELYFER,%20Marie-Noelle&MATONTI,%20F.&rft.genre=article |
